prostate cancer
Item
histologically proven diagnosis of prostate cancer
boolean
C0600139 (UMLS CUI [1])
orchiectomy; luteinizing hormone releasing hormone agonists
Item
evidence of psa progression despite castrate levels of testosterone (<50 ng/dl) following orchiectomy or during therapy with luteinizing hormone releasing hormone agonists (lhrh-a)
boolean
C0029189 (UMLS CUI [1])
C1518041 (UMLS CUI [2])
metastatic disease
Item
patients with non-metastatic or stable metastatic disease
boolean
C0027627 (UMLS CUI [1])
chromogranin; Enzyme-Linked Immunosorbent Assay; Immunoradiometric Assays
Item
chromogranin a elevation above normal range (confirmed by a second evaluation at least 1 week later) [cut off levels will be > 20 u/l for enzyme linked immunosorbent (elisa) assay and > 100 ng/ml for immunoradiometric (irma) assay]
boolean
C0008586 (UMLS CUI [1])
C0014441 (UMLS CUI [2])
C0021073 (UMLS CUI [3])
chemotherapy docetaxel
Item
patients who according to the investigator opinion are candidates to be treated immediately with chemotherapy (e.g. docetaxel)
boolean
C0392920 (UMLS CUI [1,1])
C0246415 (UMLS CUI [1,2])
antiandrogen therapy
Item
first line treatment with antiandrogen in monotherapy
boolean
C0279492 (UMLS CUI [1])
metastasis
Item
visceral metastasis
boolean
C0027627 (UMLS CUI [1])
concomitant treatment somatostatin analogue
Item
previous or concomitant treatment with a somatostatin analogue
boolean
C1707479 (UMLS CUI [1,1])
C0732165 (UMLS CUI [1,2])